CSL040

CSL040 is a soluble, recombinant fragment of the complement receptor 1 (CR1) extracellular domain. It functions as an inhibitor of all three pathways of the complement system—classical, lectin, and alternative—by binding to and regulating complement activation. The drug is being developed primarily for conditions involving acute complement-mediated tissue damage and inflammation, with a focus on transplant rejection. Preclinical studies have demonstrated that CSL040 has favorable pharmacodynamic activity consistent with its mechanism of action and an acceptable safety profile in animal models. Clinical development is ongoing in Phase 1 trials to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy subjects[1][2][3][5][8].

Other names

soluble complement receptor 1sCR1 fragmentsCR-1 fragmentsCR 1 fragmentrecombinant soluble complement receptor 1